SG11202007652UA - Camk2d antisense oligonucleotides and uses thereof - Google Patents
Camk2d antisense oligonucleotides and uses thereofInfo
- Publication number
- SG11202007652UA SG11202007652UA SG11202007652UA SG11202007652UA SG11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA SG 11202007652U A SG11202007652U A SG 11202007652UA
- Authority
- SG
- Singapore
- Prior art keywords
- camk2d
- antisense oligonucleotides
- antisense
- oligonucleotides
- camk2d antisense
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/32—Devices for opening or enlarging the visual field, e.g. of a tube of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
- A61B17/0206—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors with antagonistic arms as supports for retractor elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00477—Coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/50—Supports for surgical instruments, e.g. articulated arms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633502P | 2018-02-21 | 2018-02-21 | |
US201862635954P | 2018-02-27 | 2018-02-27 | |
US201862665998P | 2018-05-02 | 2018-05-02 | |
US201862778679P | 2018-12-12 | 2018-12-12 | |
PCT/US2019/018947 WO2019165067A1 (fr) | 2018-02-21 | 2019-02-21 | Oligonucléotides antisens camk2d et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007652UA true SG11202007652UA (en) | 2020-09-29 |
Family
ID=65729436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007652UA SG11202007652UA (en) | 2018-02-21 | 2019-02-21 | Camk2d antisense oligonucleotides and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US11058767B2 (fr) |
EP (1) | EP3755800A1 (fr) |
JP (1) | JP2021513861A (fr) |
KR (1) | KR20200140805A (fr) |
CN (1) | CN112020559A (fr) |
AU (1) | AU2019226001A1 (fr) |
BR (1) | BR112020016347A2 (fr) |
CA (1) | CA3091789A1 (fr) |
IL (1) | IL276549A (fr) |
MX (1) | MX2020008581A (fr) |
SG (1) | SG11202007652UA (fr) |
WO (1) | WO2019165067A1 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1814474B1 (fr) | 2004-11-24 | 2011-09-14 | Samy Abdou | Dispositifs de placement d'un dispositif orthopedique intervertebral |
US8764806B2 (en) | 2009-12-07 | 2014-07-01 | Samy Abdou | Devices and methods for minimally invasive spinal stabilization and instrumentation |
US8845728B1 (en) | 2011-09-23 | 2014-09-30 | Samy Abdou | Spinal fixation devices and methods of use |
US20130226240A1 (en) | 2012-02-22 | 2013-08-29 | Samy Abdou | Spinous process fixation devices and methods of use |
US9198767B2 (en) | 2012-08-28 | 2015-12-01 | Samy Abdou | Devices and methods for spinal stabilization and instrumentation |
US9320617B2 (en) | 2012-10-22 | 2016-04-26 | Cogent Spine, LLC | Devices and methods for spinal stabilization and instrumentation |
US10857003B1 (en) | 2015-10-14 | 2020-12-08 | Samy Abdou | Devices and methods for vertebral stabilization |
US10898175B2 (en) * | 2016-10-04 | 2021-01-26 | Jgmg Bengochea, Llc | Retractor extension clip systems |
US10973648B1 (en) | 2016-10-25 | 2021-04-13 | Samy Abdou | Devices and methods for vertebral bone realignment |
US10744000B1 (en) | 2016-10-25 | 2020-08-18 | Samy Abdou | Devices and methods for vertebral bone realignment |
WO2019165067A1 (fr) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Oligonucléotides antisens camk2d et leurs utilisations |
US11806250B2 (en) | 2018-02-22 | 2023-11-07 | Warsaw Orthopedic, Inc. | Expandable spinal implant system and method of using same |
US11179248B2 (en) | 2018-10-02 | 2021-11-23 | Samy Abdou | Devices and methods for spinal implantation |
KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
US11602337B2 (en) | 2019-04-24 | 2023-03-14 | Nuvasive, Inc. | Transmission assembly |
JP7337964B2 (ja) | 2019-06-18 | 2023-09-04 | ニューヴェイジヴ,インコーポレイテッド | 組織牽引システム |
US11547395B2 (en) | 2019-06-18 | 2023-01-10 | Nuvasive, Inc. | Tissue retraction system |
CN110731803B (zh) * | 2019-11-20 | 2021-05-25 | 吕振乾 | 一种心外科手术辅助器 |
WO2021158810A1 (fr) | 2020-02-05 | 2021-08-12 | Bristol-Myers Squibb Company | Oligonucléotides pour la modulation d'épissage de camk2d |
US11224415B1 (en) * | 2020-07-10 | 2022-01-18 | Warsaw Orthopedic, Inc. | Tissue retractor |
US11376134B1 (en) | 2020-11-05 | 2022-07-05 | Warsaw Orthopedic, Inc. | Dual expanding spinal implant, system, and method of use |
US11638653B2 (en) | 2020-11-05 | 2023-05-02 | Warsaw Orthopedic, Inc. | Surgery instruments with a movable handle |
US11395743B1 (en) | 2021-05-04 | 2022-07-26 | Warsaw Orthopedic, Inc. | Externally driven expandable interbody and related methods |
US11291554B1 (en) | 2021-05-03 | 2022-04-05 | Medtronic, Inc. | Unibody dual expanding interbody implant |
US11285014B1 (en) | 2020-11-05 | 2022-03-29 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system, and method |
US11963881B2 (en) | 2020-11-05 | 2024-04-23 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system, and method |
US11564724B2 (en) | 2020-11-05 | 2023-01-31 | Warsaw Orthopedic, Inc. | Expandable inter-body device, system and method |
US11517443B2 (en) | 2020-11-05 | 2022-12-06 | Warsaw Orthopedic, Inc. | Dual wedge expandable implant, system and method of use |
US11833059B2 (en) | 2020-11-05 | 2023-12-05 | Warsaw Orthopedic, Inc. | Expandable inter-body device, expandable plate system, and associated methods |
WO2022251644A1 (fr) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Cellules immunitaires déficientes en nr4a3 et leurs utilisations |
US11612499B2 (en) | 2021-06-24 | 2023-03-28 | Warsaw Orthopedic, Inc. | Expandable interbody implant |
US11730608B2 (en) | 2021-07-13 | 2023-08-22 | Warsaw Orthopedic, Inc. | Monoblock expandable interbody implant |
WO2023064924A1 (fr) | 2021-10-14 | 2023-04-20 | Codiak Biosciences, Inc. | Cellules productrices modifiées pour la production de vésicules extracellulaires |
US11850163B2 (en) | 2022-02-01 | 2023-12-26 | Warsaw Orthopedic, Inc. | Interbody implant with adjusting shims |
WO2023225665A1 (fr) | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | Polynucléotides ciblant nr4a3 et leurs utilisations |
WO2024064952A1 (fr) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Procédés de culture de cellules déficientes en nr4a surexprimant c-jun |
WO2024077174A1 (fr) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Procédés de culture de cellules déficientes en nr4a |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3749088A (en) | 1971-06-23 | 1973-07-31 | W Kohlmann | Surgical retractor device |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
US6057111A (en) | 1996-11-13 | 2000-05-02 | Quark Biotech, Inc. | Gene identification method |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
DE04020014T1 (de) | 1997-09-12 | 2006-01-26 | Exiqon A/S | Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga |
US6139493A (en) * | 1998-07-08 | 2000-10-31 | Koros; Tibor B. | Retractor with adjustable length blades and light pipe guides |
EP1152009B2 (fr) | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Nouveaux analogues de nucleosides et d'oligonucleotides |
NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
GB2375172A (en) | 2000-02-07 | 2002-11-06 | Quark Biotech Inc | Fas pathway genes |
EP1355578A1 (fr) * | 2001-01-29 | 2003-10-29 | Stephen Ritland | Ecarteur et procede servant a placer une vis de pedicule vertebral |
EP1478772A2 (fr) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur |
WO2005060667A2 (fr) | 2003-12-19 | 2005-07-07 | The General Hospital Corporation | Sequences d'acides nucleiques et d'acides amines associees a la douleur |
US20070072178A1 (en) | 2001-11-05 | 2007-03-29 | Torsten Haferlach | Novel genetic markers for leukemias |
WO2003065006A2 (fr) | 2002-01-31 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Procedes et compositions pour le traitement du cancer utilisant les molecules 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10 |
US20040101855A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of PPAR binding protein expression |
US9259144B2 (en) | 2002-07-11 | 2016-02-16 | Nuvasive, Inc. | Surgical access system and related methods |
WO2004012817A2 (fr) | 2002-07-31 | 2004-02-12 | Kylix B.V. | Utilisation des genes identifies comme etant impliques dans la croissance tumorale, destinee au developpement de medicaments anticancereux |
JP2006513701A (ja) | 2002-10-11 | 2006-04-27 | アーラム バイオシステムズ インコーポレイテッド | 核酸ベースのシグナルトランスデューサーを含む立体構造的に敏感なプローブを有する標的検出システム |
US7850608B2 (en) | 2002-10-25 | 2010-12-14 | K2M, Inc. | Minimal incision maximal access MIS spine instrumentation and method |
EP2141233B1 (fr) | 2002-11-18 | 2016-10-19 | Roche Innovation Center Copenhagen A/S | Conception antisens |
US7691057B2 (en) | 2003-01-16 | 2010-04-06 | Nuvasive, Inc. | Surgical access system and related methods |
US7256200B2 (en) | 2003-02-10 | 2007-08-14 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Method and composition for potentiating an oplate analgesic |
US7819801B2 (en) | 2003-02-27 | 2010-10-26 | Nuvasive, Inc. | Surgical access system and related methods |
US20050085436A1 (en) | 2003-07-08 | 2005-04-21 | Hao Li | Method to treat conditions associated with insulin signalling dysregulation |
US7481766B2 (en) | 2003-08-14 | 2009-01-27 | Synthes (U.S.A.) | Multiple-blade retractor |
US20050137461A1 (en) * | 2003-12-18 | 2005-06-23 | Depuy Spine, Inc. | Telescoping blade assembly and instruments for adjusting an adjustable blade |
US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
WO2006042241A2 (fr) | 2004-10-08 | 2006-04-20 | Nuvasive, Inc. | Procedes et systeme d'acces a un site chirurgical |
JP2006223228A (ja) | 2005-02-18 | 2006-08-31 | Dainippon Sumitomo Pharma Co Ltd | 自己免疫疾患治療剤のスクリーニング方法 |
US20060287584A1 (en) * | 2005-06-16 | 2006-12-21 | Javier Garcia-Bengochia | Surgical retractor extensions |
CN1904900A (zh) * | 2005-07-28 | 2007-01-31 | 中国科学院生物物理研究所 | 人类的内源性siRNA序列及其应用和筛选方法 |
WO2007031091A2 (fr) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Composes antagonistes d'arn de modulation de l'expression de p21 ras |
EP1962888A2 (fr) * | 2005-11-18 | 2008-09-03 | Myogen, Inc. | Procedes de traitement et utilisations pour la camkii et son interaction avec des hdacs et des calpaines |
KR20130042043A (ko) | 2006-01-27 | 2013-04-25 | 아이시스 파마수티컬즈 인코포레이티드 | 6-변형된 바이시클릭 핵산 유사체 |
CA2644162A1 (fr) * | 2006-03-07 | 2007-09-13 | Telethon Institute For Child Health Research | Procede permettant de diagnostiquer et/ou de prevoir le developpement d'un trouble allergique et agents de traitement et/ou de prevention correspondants |
JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ, インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
WO2007134181A2 (fr) | 2006-05-11 | 2007-11-22 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques bicycliques modifiés en 5' |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
WO2008020435A2 (fr) | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions et procédés pour le traitement de troubles de l'humeur |
ES2534430T3 (es) | 2006-08-28 | 2015-04-22 | The University Of Western Australia | Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN |
GB0617222D0 (en) | 2006-08-31 | 2006-10-11 | Vereniging Het Nl Kanker I | Antibiotics |
US8062217B2 (en) * | 2007-01-26 | 2011-11-22 | Theken Spine, Llc | Surgical retractor with removable blades and method of use |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
WO2008152636A2 (fr) * | 2007-06-15 | 2008-12-18 | Quark Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression de la nadph oxydase |
AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
DE202007012284U1 (de) | 2007-09-01 | 2007-10-25 | Aesculap Ag & Co. Kg | Chirurgischer Retraktor |
WO2009067647A1 (fr) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Analogues d'acide nucléique alpha-l-bicyclique carbocyclique |
US8841423B2 (en) | 2008-04-28 | 2014-09-23 | University Of Iowa Research Foundation | Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
EP2177615A1 (fr) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales |
US8226554B2 (en) | 2008-10-30 | 2012-07-24 | Warsaw Orthopedic, Inc. | Retractor assemblies for surgery in a patient |
WO2010120969A1 (fr) | 2009-04-15 | 2010-10-21 | Board Of Regents, The University Of Texas System | Ciblage de la famille mir-30 et de la famille let-7 pour le traitement de la maladie cardiaque |
ES2555057T3 (es) * | 2009-06-12 | 2015-12-28 | Roche Innovation Center Copenhagen A/S | Nuevos potentes compuestos antisentido anti-ApoB |
US8563528B2 (en) * | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
EP2462153B1 (fr) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques cyclohexoses bicycliques |
WO2011048125A1 (fr) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Administration orale d'oligonucléotides de lna thérapeutiquement efficaces |
US9737288B2 (en) * | 2010-03-11 | 2017-08-22 | Globus Medical, Inc | Tissue retractor and methods of use |
WO2011156202A1 (fr) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | 2'‑amino- et 2'‑thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers |
EP2606130B1 (fr) | 2010-08-16 | 2019-03-13 | Duke University | Camkk-bêta en tant que marqueur du cancer de la prostate |
WO2013023084A2 (fr) | 2011-08-09 | 2013-02-14 | Fred Hutchinson Cancer Research Center | Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc |
EP2751270B1 (fr) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Complexes oligomère-conjugué et leur utilisation |
US9603949B2 (en) * | 2011-09-01 | 2017-03-28 | University Of Iowa Research Foundation | Oligonucleotide-based probes for detection of bacterial nucleases |
AU2012301617A1 (en) | 2011-09-02 | 2014-04-17 | Salk Institute For Biological Studies | CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity |
KR20140067092A (ko) | 2011-09-07 | 2014-06-03 | 마리나 바이오테크, 인크. | 형태적으로 제한된 단량체를 갖는 핵산 화합물의 합성 및 용도 |
US9637740B2 (en) | 2012-04-02 | 2017-05-02 | President And Fellows Of Harvard College | Cancer treatment and immune system regulation through FAT10 pathway inhibition |
EP2850092B1 (fr) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Analogues tricycliques d'acide nucléique |
JP2016522674A (ja) * | 2012-05-16 | 2016-08-04 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
WO2014077693A1 (fr) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Moyens et procédés pour réduire un effet du vieillissement dans une cellule de mammifère |
US9951061B2 (en) | 2013-03-06 | 2018-04-24 | Allosteros Therapeutics, Inc. | CaMKII inhibitors and uses thereof |
WO2014179492A1 (fr) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Polythérapie pour traiter les arythmies ou l'insuffisance cardiaque |
JP6387084B2 (ja) | 2013-05-01 | 2018-09-05 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | アポリポタンパク質c−iiiの発現を調節するための組成物および方法 |
EP3591054A1 (fr) * | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Oligomères et conjugués antisens ciblant pcsk9 |
JP6782227B2 (ja) | 2014-09-05 | 2020-11-11 | ザ・ジョンズ・ホプキンス・ユニバーシティー | CaMKII阻害剤及びその使用 |
PT3265563T (pt) | 2015-02-02 | 2021-06-03 | Meiragtx Uk Ii Ltd | Regulação da expressão genética por modulação mediada por aptâmero de splicing alternativo |
WO2016170348A2 (fr) | 2015-04-22 | 2016-10-27 | Mina Therapeutics Limited | Compositions de petits arn et méthodes d'utilisation |
WO2017011286A1 (fr) * | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la sous-unité acide labile de la protéine se liant au facteur de croissance apparenté a l'insuline (igfals) et du facteur de croissance 1 apparenté a l'insuline (igf-1) et leurs procédés d'utilisation |
EP3353305A4 (fr) | 2015-09-25 | 2019-09-18 | Ionis Pharmaceuticals, Inc. | Composés antisens conjugués et leur utilisation |
WO2017053999A1 (fr) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Composés conjugués antisens et leur utilisation |
WO2017106283A1 (fr) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions et procédés de traitement de maladies hépatiques |
EP3481857A1 (fr) * | 2016-07-06 | 2019-05-15 | Crispr Therapeutics AG | Matériaux et méthodes de traitement de troubles liés à la douleur |
WO2018025085A2 (fr) | 2016-08-03 | 2018-02-08 | Meiragtx Uk Ii Limited | Criblage à haut débit à base de cellules pour les aptamères |
EP3681489A4 (fr) | 2017-09-10 | 2021-05-26 | Carmel Haifa University Economic Corporation Ltd. | Méthode de traitement de la dépression et du trouble dépressif majeur |
WO2019143847A1 (fr) | 2018-01-18 | 2019-07-25 | Advanced ReGen Medical Technologies, LLC | Compositions thérapeutiques et leurs procédés de préparation et d'utilisation |
WO2019165067A1 (fr) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Oligonucléotides antisens camk2d et leurs utilisations |
WO2019217459A1 (fr) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Administration extra-hépatique |
-
2019
- 2019-02-21 WO PCT/US2019/018947 patent/WO2019165067A1/fr unknown
- 2019-02-21 SG SG11202007652UA patent/SG11202007652UA/en unknown
- 2019-02-21 AU AU2019226001A patent/AU2019226001A1/en active Pending
- 2019-02-21 BR BR112020016347-3A patent/BR112020016347A2/pt unknown
- 2019-02-21 EP EP19710527.3A patent/EP3755800A1/fr active Pending
- 2019-02-21 US US16/282,138 patent/US11058767B2/en active Active
- 2019-02-21 KR KR1020207026765A patent/KR20200140805A/ko not_active Application Discontinuation
- 2019-02-21 MX MX2020008581A patent/MX2020008581A/es unknown
- 2019-02-21 CN CN201980025466.8A patent/CN112020559A/zh active Pending
- 2019-02-21 US US16/281,138 patent/US11083444B2/en active Active
- 2019-02-21 CA CA3091789A patent/CA3091789A1/fr active Pending
- 2019-02-21 JP JP2020544270A patent/JP2021513861A/ja active Pending
-
2020
- 2020-08-06 IL IL276549A patent/IL276549A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020008581A (es) | 2020-09-21 |
WO2019165067A1 (fr) | 2019-08-29 |
CA3091789A1 (fr) | 2019-08-29 |
US20190321022A1 (en) | 2019-10-24 |
BR112020016347A2 (pt) | 2021-01-12 |
US11058767B2 (en) | 2021-07-13 |
IL276549A (en) | 2020-09-30 |
EP3755800A1 (fr) | 2020-12-30 |
AU2019226001A1 (en) | 2020-09-03 |
US11083444B2 (en) | 2021-08-10 |
CN112020559A (zh) | 2020-12-01 |
JP2021513861A (ja) | 2021-06-03 |
US20190275148A1 (en) | 2019-09-12 |
KR20200140805A (ko) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276549A (en) | CAMK2D antisense oligonucleotides and their uses | |
IL268422A (en) | Targeted oligonucleotides | |
HK1248276A1 (zh) | Tau 反義低聚物及其用途 | |
IL275950A (en) | Antisense alpha-synuclein oligonucleotides and their use | |
GB201711809D0 (en) | Antisense oligonucleotide | |
IL293377A (en) | hsd17b13 variants and their uses | |
IL269714A (en) | Oligonucleotide probes and their uses | |
GB201904709D0 (en) | Chemically modified oligonucleotides | |
IL275903A (en) | Antisense oligonucleotides directed against alpha-synculin and their uses | |
IL275902A (en) | Antisense oligonucleotides directed against alpha-synculin and their uses | |
SG10201913477UA (en) | G-quadruplex-containing antisense oligonucleotides | |
IL260193A (en) | Tlr inhibitory oligonucleotides and their use | |
EP3724206A4 (fr) | Composés antisens conjugués et leur utilisation | |
IL280581A (en) | RNAi variant against alpha-synuclein | |
SG10201609048RA (en) | Antisense oligonucleotides | |
SG10202008771WA (en) | Combination therapy with liposomal antisense oligonucleotides | |
EP4041248A4 (fr) | Oligonucléotides modifiés | |
GB201714409D0 (en) | Oligonucleotides and analogues thereof | |
IL286826A (en) | angptl2 oligonucleotides and their use | |
EP4069844A4 (fr) | Oligonucléotides anti-slc6a1 et procédés associés | |
GB201704374D0 (en) | Improved metering systems and methods | |
SG11202008247WA (en) | Matrix metalloproteinase-1 antisense oligonucleotides | |
SG11202012829RA (en) | Acetyl-coa carboxylase2 antisense oligonucleotides | |
GB201714330D0 (en) | Oligonucleotides | |
EP3565825A4 (fr) | Oligonucléotides antisens snap25 |